Adiponectin: Its role in obesity-associated colon and prostate cancers

Santoshi Muppala; Siva K.P. Konduru; Neha Merchant; Judy Ramsoondar; Carlos Karan Rampersad; Balney Rajitha; Vidya Mukund; Jyothsna Kancherla; Anthea Hammond; Tapan Kumar Barik; Mastan Mannarapu; Afroz Alam; Riyaz Basha; Pallaval Veera Bramhachari; Dheeraj Verma; Pinninti Santosh Sushma; Subasini Pattnaik; Ganji Purnachandra Nagaraju

doi:10.1016/j.critrevonc.2017.06.003

Adiponectin: Its role in obesity-associated colon and prostate cancers

Santoshi Muppala, Siva K.P. Konduru, Neha Merchant, Judy Ramsoondar, Carlos Karan Rampersad, Balney Rajitha, Vidya Mukund, Jyothsna Kancherla, Anthea Hammond, Tapan Kumar Barik, Mastan Mannarapu, Afroz Alam, Riyaz Basha, Pallaval Veera Bramhachari, Dheeraj Verma, Pinninti Santosh Sushma, Subasini Pattnaik, Ganji Purnachandra Nagaraju

Pediatrics

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

Adipose tissue synthesizes many proteins and hormones collectively called adipokines, which are linked to a number of diseases, including cancer. Low levels of adiponectin are reported to be a risk factor for obesity-related cancers including colorectal and prostate cancers. Accordingly, obesity/lifestyle-related diseases, including certain cancers, may be treated by developing drugs that act specifically on adiponectin levels in circulation. Adiponectin may also serve as a clinical biomarker in obesity-related diseases. Adiponectin-based therapies are known to inhibit cancer advancement and thus may provide a therapeutic approach to delay cancer progression. Better understanding of the function of adiponectin is of great significance in the fight against cancer. This timely review is concentrated on the role of adiponectin and the impact of obesity on the development of cancers, especially colorectal and prostate cancers.

Original language	English
Pages (from-to)	125-133
Number of pages	9
Journal	Critical Reviews in Oncology/Hematology
Volume	116
DOIs	https://doi.org/10.1016/j.critrevonc.2017.06.003
State	Published - 1 Aug 2017

Keywords

Adiponectin
Adiponectin receptors
Colorectal cancer
Obesity
Prostate cancer

Access to Document

10.1016/j.critrevonc.2017.06.003

Cite this

Muppala, S., Konduru, S. K. P., Merchant, N., Ramsoondar, J., Rampersad, C. K., Rajitha, B., Mukund, V., Kancherla, J., Hammond, A., Barik, T. K., Mannarapu, M., Alam, A., Basha, R., Bramhachari, P. V., Verma, D., Sushma, P. S., Pattnaik, S., & Nagaraju, G. P. (2017). Adiponectin: Its role in obesity-associated colon and prostate cancers. Critical Reviews in Oncology/Hematology, 116, 125-133. https://doi.org/10.1016/j.critrevonc.2017.06.003

@article{c88a003801c74e8ea6a263985e65f677,

title = "Adiponectin: Its role in obesity-associated colon and prostate cancers",

abstract = "Adipose tissue synthesizes many proteins and hormones collectively called adipokines, which are linked to a number of diseases, including cancer. Low levels of adiponectin are reported to be a risk factor for obesity-related cancers including colorectal and prostate cancers. Accordingly, obesity/lifestyle-related diseases, including certain cancers, may be treated by developing drugs that act specifically on adiponectin levels in circulation. Adiponectin may also serve as a clinical biomarker in obesity-related diseases. Adiponectin-based therapies are known to inhibit cancer advancement and thus may provide a therapeutic approach to delay cancer progression. Better understanding of the function of adiponectin is of great significance in the fight against cancer. This timely review is concentrated on the role of adiponectin and the impact of obesity on the development of cancers, especially colorectal and prostate cancers.",

keywords = "Adiponectin, Adiponectin receptors, Colorectal cancer, Obesity, Prostate cancer",

author = "Santoshi Muppala and Konduru, {Siva K.P.} and Neha Merchant and Judy Ramsoondar and Rampersad, {Carlos Karan} and Balney Rajitha and Vidya Mukund and Jyothsna Kancherla and Anthea Hammond and Barik, {Tapan Kumar} and Mastan Mannarapu and Afroz Alam and Riyaz Basha and Bramhachari, {Pallaval Veera} and Dheeraj Verma and Sushma, {Pinninti Santosh} and Subasini Pattnaik and Nagaraju, {Ganji Purnachandra}",

year = "2017",

month = aug,

day = "1",

doi = "10.1016/j.critrevonc.2017.06.003",

language = "English",

volume = "116",

pages = "125--133",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

Muppala, S, Konduru, SKP, Merchant, N, Ramsoondar, J, Rampersad, CK, Rajitha, B, Mukund, V, Kancherla, J, Hammond, A, Barik, TK, Mannarapu, M, Alam, A, Basha, R, Bramhachari, PV, Verma, D, Sushma, PS, Pattnaik, S & Nagaraju, GP 2017, 'Adiponectin: Its role in obesity-associated colon and prostate cancers', Critical Reviews in Oncology/Hematology, vol. 116, pp. 125-133. https://doi.org/10.1016/j.critrevonc.2017.06.003

TY - JOUR

T1 - Adiponectin

T2 - Its role in obesity-associated colon and prostate cancers

AU - Muppala, Santoshi

AU - Konduru, Siva K.P.

AU - Merchant, Neha

AU - Ramsoondar, Judy

AU - Rampersad, Carlos Karan

AU - Rajitha, Balney

AU - Mukund, Vidya

AU - Kancherla, Jyothsna

AU - Hammond, Anthea

AU - Barik, Tapan Kumar

AU - Mannarapu, Mastan

AU - Alam, Afroz

AU - Basha, Riyaz

AU - Bramhachari, Pallaval Veera

AU - Verma, Dheeraj

AU - Sushma, Pinninti Santosh

AU - Pattnaik, Subasini

AU - Nagaraju, Ganji Purnachandra

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Adipose tissue synthesizes many proteins and hormones collectively called adipokines, which are linked to a number of diseases, including cancer. Low levels of adiponectin are reported to be a risk factor for obesity-related cancers including colorectal and prostate cancers. Accordingly, obesity/lifestyle-related diseases, including certain cancers, may be treated by developing drugs that act specifically on adiponectin levels in circulation. Adiponectin may also serve as a clinical biomarker in obesity-related diseases. Adiponectin-based therapies are known to inhibit cancer advancement and thus may provide a therapeutic approach to delay cancer progression. Better understanding of the function of adiponectin is of great significance in the fight against cancer. This timely review is concentrated on the role of adiponectin and the impact of obesity on the development of cancers, especially colorectal and prostate cancers.

AB - Adipose tissue synthesizes many proteins and hormones collectively called adipokines, which are linked to a number of diseases, including cancer. Low levels of adiponectin are reported to be a risk factor for obesity-related cancers including colorectal and prostate cancers. Accordingly, obesity/lifestyle-related diseases, including certain cancers, may be treated by developing drugs that act specifically on adiponectin levels in circulation. Adiponectin may also serve as a clinical biomarker in obesity-related diseases. Adiponectin-based therapies are known to inhibit cancer advancement and thus may provide a therapeutic approach to delay cancer progression. Better understanding of the function of adiponectin is of great significance in the fight against cancer. This timely review is concentrated on the role of adiponectin and the impact of obesity on the development of cancers, especially colorectal and prostate cancers.

KW - Adiponectin

KW - Adiponectin receptors

KW - Colorectal cancer

KW - Obesity

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85024849369&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.06.003

DO - 10.1016/j.critrevonc.2017.06.003

M3 - Review article

C2 - 28693794

AN - SCOPUS:85024849369

SN - 1040-8428

VL - 116

SP - 125

EP - 133

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

ER -

Adiponectin: Its role in obesity-associated colon and prostate cancers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this